Nathan den Broeder

710 total citations
59 papers, 430 citations indexed

About

Nathan den Broeder is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Nathan den Broeder has authored 59 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Rheumatology, 17 papers in Immunology and 16 papers in Genetics. Recurrent topics in Nathan den Broeder's work include Rheumatoid Arthritis Research and Therapies (28 papers), Inflammatory Bowel Disease (11 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Nathan den Broeder is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (28 papers), Inflammatory Bowel Disease (11 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Nathan den Broeder collaborates with scholars based in Netherlands, Canada and United States. Nathan den Broeder's co-authors include Alfons A den Broeder, F.H.J. van den Hoogen, Aatke van der Maas, Lise M Verhoef, Frank Hoentjen, Tessa E H Römkens, Bart J. F. van den Bemt, Noortje van Herwaarden, Rogier M. Thurlings and Rachel West and has published in prestigious journals such as Annals of Internal Medicine, Gut and Annals of the Rheumatic Diseases.

In The Last Decade

Nathan den Broeder

51 papers receiving 427 citations

Peers

Nathan den Broeder
Maryam Adas United Kingdom
Chamaida Plasencia Spain
Árni Jón Geirsson Iceland
Mark C. Parish United States
X. Mariette France
Fanny Tabarin France
Ewa Więsik–Szewczyk Poland
Dan‐Avi Landau United States
Annet van Royen Netherlands
Emma Vernon United States
Maryam Adas United Kingdom
Nathan den Broeder
Citations per year, relative to Nathan den Broeder Nathan den Broeder (= 1×) peers Maryam Adas

Countries citing papers authored by Nathan den Broeder

Since Specialization
Citations

This map shows the geographic impact of Nathan den Broeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan den Broeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan den Broeder more than expected).

Fields of papers citing papers by Nathan den Broeder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan den Broeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan den Broeder. The network helps show where Nathan den Broeder may publish in the future.

Co-authorship network of co-authors of Nathan den Broeder

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan den Broeder. A scholar is included among the top collaborators of Nathan den Broeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan den Broeder. Nathan den Broeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vriezekolk, Johanna E, Nathan den Broeder, Alfons A den Broeder, et al.. (2025). Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study. RMD Open. 11(2). e005566–e005566.
2.
Broeder, Nathan den, et al.. (2025). Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis. Annals of Internal Medicine. 178(10). 1400–1408.
3.
4.
5.
Broeder, Nathan den, Debora de Jong, Marjolijn Duijvestein, et al.. (2024). OP15 High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trial. Journal of Crohn s and Colitis. 18(Supplement_1). i29–i30. 4 indexed citations
6.
7.
Broeder, Nathan den, Alfons A den Broeder, Lise M Verhoef, et al.. (2023). Non‐Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study. Clinical Pharmacology & Therapeutics. 114(4). 810–814. 3 indexed citations
8.
Broeder, Alfons A den, et al.. (2023). 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. The Lancet Rheumatology. 5(4). e208–e214. 15 indexed citations
9.
Smits, Lisa, et al.. (2023). Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy. Digestive Diseases and Sciences. 68(7). 2936–2945.
10.
Derikx, Lauranne, et al.. (2022). P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis. Journal of Crohn s and Colitis. 16(Supplement_1). i422–i423. 2 indexed citations
11.
Broeder, Nathan den, F.H.J. van den Hoogen, E. Mahler, et al.. (2022). Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Annals of the Rheumatic Diseases. 81(10). 1392–1399. 21 indexed citations
12.
13.
Broeder, Nathan den, et al.. (2021). Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Lara D. Veeken. 61(6). 2307–2315. 10 indexed citations
14.
Broeder, Nathan den, Mark H. Wenink, Aatke van der Maas, et al.. (2020). Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. Trials. 21(1). 90–90. 11 indexed citations
15.
Broeder, Nathan den, Alfons A den Broeder, Noortje van Herwaarden, et al.. (2019). SAT0651 GOOD DISCRIMINATIVE ABILITY OF THE SIMPLE EROSION NARROWING SCORE COMPARED TO THE SHARP/VAN DER HEIJDE SCORE. Annals of the Rheumatic Diseases. 78. 1424–1424. 2 indexed citations
16.
Maas, Aatke van der, et al.. (2019). OP0145 NORMAL VERSUS ELEVATED ACUTE PHASE REACTANTS IN PATIENTS WITH POLYMYALGIA RHEUMATICA: ARE THESE DIFFERENT SUBSETS?. Annals of the Rheumatic Diseases. 78. 148–148. 1 indexed citations
17.
Verhoef, Lise M, Nathan den Broeder, Rogier M. Thurlings, et al.. (2019). Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. The Lancet Rheumatology. 1(3). e145–e153. 23 indexed citations
18.
Tweehuysen, Lieke, Nathan den Broeder, Noortje van Herwaarden, et al.. (2018). Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 4(1). e000654–e000654. 29 indexed citations
19.
Broeder, Nathan den, Ester Piek, Steven Teerenstra, et al.. (2017). The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysis.. PubMed. 35(3). 379–383. 2 indexed citations
20.
Broeder, Alfons A den, Lise M Verhoef, Jaap Fransen, et al.. (2017). Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials. 18(1). 403–403. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maryam Adas Breakdown of academic impact, for papers by Chamaida Plasencia Breakdown of academic impact, for papers by Árni Jón Geirsson Breakdown of academic impact, for papers by Mark C. Parish Breakdown of academic impact, for papers by X. Mariette Breakdown of academic impact, for papers by Fanny Tabarin Breakdown of academic impact, for papers by Ewa Więsik–Szewczyk Breakdown of academic impact, for papers by Dan‐Avi Landau Breakdown of academic impact, for papers by Annet van Royen Breakdown of academic impact, for papers by Emma Vernon
Rankless by CCL
2026